History

MK-677 was developed at Merck Research Laboratories in the mid-1990s (first as L-163,191, then MK-0677) as an orally active, non-peptide successor to Merck's earlier GH-releasing peptides. The landmark discovery paper (Patchett et al., PNAS 1995) described it as a potent oral growth hormone secretagogue. Human trials followed through the 2000s — including a 2-year trial in older adults and a Merck-funded Alzheimer's trial — but Merck never sought approval. Rights later moved to Lumos Pharma, which is developing it as LUM-201 for pediatric growth hormone deficiency, the only active legitimate program.

MK-677, also called ibutamoren, is one of the more unusual entries in any peptide reference — because it is not a peptide. It is a synthetic small molecule that fools the body into releasing more of its own growth hormone, and unlike most compounds marketed to the fitness and “anti-aging” crowd, it has been studied in real, randomized human trials, including a two-year study and a 563-patient Alzheimer’s trial. That is far more evidence than most of its shelf-mates can claim. The catch is what the evidence shows: MK-677 reliably moves the lab numbers everyone points to, but no trial has ever shown it produces a meaningful real-world benefit for any of the things it is sold for.

What it is

MK-677 is a potent, long-acting, orally active agonist of the growth-hormone-secretagogue receptor (GHSR-1a) — the same receptor activated by the natural hormone ghrelin. It is worth stating plainly for a peptide audience: MK-677 is not a peptide. It is a synthetic small organic molecule (a spiropiperidine-derived structure), formula C27H36N4O5S, molar mass roughly 528.7 g/mol. That chemistry is why it survives oral dosing and lasts a long time in the body, whereas true GH-releasing peptides such as ipamorelin or GHRP-6 are injected and short-lived.

The mechanism is indirect. By binding GHSR-1a in the pituitary and hypothalamus, MK-677 amplifies the body’s own pulsatile release of growth hormone (GH), which in turn raises insulin-like growth factor-1 (IGF-1). A single oral dose elevates GH and keeps IGF-1 raised for about 24 hours, which is what makes once-daily use feasible. Because it works through the natural pulsatile axis rather than injecting GH directly, the GH rise is somewhat physiologic. But it is not “side-effect free”: it raises cortisol in several studies (usually transiently) and stimulates appetite, a predictable ghrelin-like effect.

One persistent piece of marketing confusion is worth correcting: MK-677 is frequently sold as a “SARM.” It is not a SARM. SARMs act on the androgen receptor; MK-677 acts on the ghrelin receptor. The label is simply wrong.

The claims

In legitimate research, MK-677 has been studied by Merck (1990s–2000s) and now Lumos Pharma (2010s–2020s) for growth hormone deficiency in children and adults, frailty and muscle wasting in the elderly, recovery after hip fracture, catabolic and wasting states, obesity, and Alzheimer’s disease (on the theory that raising IGF-1 might help clear amyloid-beta).

On the gray market it is promoted very differently — as a muscle-builder, fat-loss aid, recovery and sleep enhancer, bone-density booster, and anti-aging compound. Almost all of these claims lean on the surrogate IGF-1 rise rather than on any trial that measured whether people actually got stronger, leaner, or healthier.

The evidence

This is the part where MK-677 stands apart: the human data exist. The problem is the results.

A two-year randomized, double-blind, placebo-controlled trial in 65 healthy adults aged 60–81 (Nass et al., Annals of Internal Medicine, 2008) is the single best long-term study. MK-677 raised GH and IGF-1 into the young-adult range and held them there for two years with no tachyphylaxis. Fat-free mass rose about 1.1 kg versus a 0.5 kg loss on placebo. Critically, that added fat-free mass produced no improvement in strength or physical function. Fasting glucose rose and insulin sensitivity worsened modestly. In other words, the surrogate markers improved and the outcomes that matter did not.

A large Alzheimer’s trial (Sevigny et al., Neurology, 2008; Merck-funded) randomized 563 patients with mild-to-moderate disease. IGF-1 rose 60.1% at six weeks and 72.9% at twelve months — clear proof the drug engaged its target — yet there was no effect on any cognitive or functional endpoint. A clean, well-powered failure.

A hip-fracture recovery trial (Adunsky et al., Archives of Gerontology and Geriatrics, 2011) randomized 123 elderly patients. Functional performance did not improve significantly, and the trial was stopped early for a congestive-heart-failure safety signal: 4 cases on MK-677 versus 1 on placebo.

Shorter, smaller studies fill in the mechanism. An 8-week trial in 24 obese men (Svensson et al., JCEM, 1998) raised GH, IGF-1, and fat-free mass, with a transient rise in metabolic rate but no significant change in total or visceral fat. A small sleep study (Copinschi et al., 1997) found increased slow-wave and REM sleep. A bone study (Murphy et al., 1999) raised bone-turnover markers — a surrogate, not fracture-rate data.

The one live thread is LUM-201 for pediatric growth hormone deficiency. Lumos Pharma’s Phase 2 trials (OraGrowtH210/212) reported annualized height velocity of roughly 8 cm/year at one year, against about 9.7 cm/year for recombinant human GH, and the company has stated intent to run a Phase 3. These are sponsor-reported, open-label, active-comparator results in children with diagnosed deficiency — not the healthy adults the gray market targets, and not yet confirmed in registration-grade trials.

Animal work was extensive and supportive, including a 2018 study in an Alzheimer’s mouse model reporting reduced amyloid pathology — a hypothesis the human Neurology trial then failed to confirm. It is a textbook case of animal promise that did not translate.

What is missing is the whole marketed case: no trial demonstrates muscle strength or function, healthful fat loss, recovery, or anti-aging in healthy adults, and there are no long-term safety trials in healthy people. The best long data — two years — is in the elderly and showed metabolic downsides. The major trials were also Merck- or sponsor-funded, which is normal but warrants the usual skepticism, especially for the favorable open-label pediatric readouts.

Safety and side effects

The most serious documented signal is cardiovascular and fluid-related: the hip-fracture trial was halted early for excess congestive heart failure (4 versus 1). Lower-extremity edema is consistently reported, and fluid retention with possible blood-pressure effects is mechanism-plausible.

Metabolically, the two-year trial found increased fasting glucose and decreased insulin sensitivity — directly relevant for anyone diabetic or prediabetic. On the endocrine side, MK-677 raises cortisol in several studies (often transiently) and raises IGF-1 substantially and chronically; the long-term implications of sustained IGF-1 elevation, including theoretical cancer-promotion concerns common to the GH/IGF-1 axis, are not established in healthy long-term users.

More common, milder effects include increased appetite, water retention and swelling, muscle or joint pain, fatigue, and nausea. And because it is sold outside regulated channels, real-world products carry an added risk: they may be under- or over-dosed or contaminated, with no quality assurance.

This is informational only and not medical advice.

Legal and regulatory status

MK-677 has never been approved for any indication anywhere. It is an investigational new drug. The FDA treats ibutamoren as excluded from the dietary-supplement definition, so products selling it as a supplement are adulterated or misbranded; the agency has issued warning letters to sellers, including Warrior Labz SARMS (June 12, 2023) and Agebox Inc. (December 19, 2025, over children’s growth supplements found to contain undeclared ibutamoren). The Department of Defense’s Operation Supplement Safety states it is not approved for human use and is not legal in dietary supplements, and is often sold deceptively under “Supplement Facts,” “Research Facts,” or “For Research Use Only” labels.

In anti-doping, WADA prohibits ibutamoren at all times under Section S2 (peptide hormones, growth factors, and mimetics), in the growth-hormone-secretagogue grouping, where it was added as a named example on the 2024 Prohibited List. It also appears on the DoD Prohibited Dietary Supplement Ingredients List.

The gray-market reality: it is widely sold online as capsules or liquid labeled “research chemical” or “SARM.” These are unapproved, unregulated products of unverified identity, purity, and dose. “Research use only” is a liability dodge, not a quality or safety guarantee.

Bottom line

MK-677 is the rare gray-market compound that has actually been put through serious human trials — and that is exactly why its weaknesses are so visible. It does what its biochemistry promises: it raises growth hormone and IGF-1, modestly increases lean mass, and may deepen sleep. But across two decades of randomized trials, those changes never turned into the outcomes people actually want — more strength, better function, healthful fat loss, cognitive benefit, or healthier aging. One trial was stopped for a heart-failure signal, and the long-term data flag worsening blood sugar. It is investigational, unapproved, banned in sport, and unlawful in supplements. The honest grade is “Preliminary human,” and it sits at the cautionary end of that band: plenty of data, consistent surrogate effects, and a discouraging record on the things that matter.

MK-677 (Ibutamoren): A Lot of Human Data, Little to Show for It